ML351 As Treatment For Stroke And Ischemic Brain Injury

Tech ID: 33275 / UC Case 2016-385-0


Lipoxygenases form a large family of enzymes capable of oxidizing arachidonic acid and related polyunsaturated fatty acids. One such lipoxygenase, 12/15 LOX can oxidize both the C-12 and C-15 of arachidonic acid, forming 12- or 15-hydroperosyarachidonic acid (12- or 15-HPETE). Lipoxygenases and their metabolites have been implicated in many diseases. In particular 12/15-LOX (also known as 15-LOX-1, 15-LOX, or 15-LO-1 in humans and L-12-LoX, leukocyte-type 12-LO, or L-12-LO in mice) plays a role in atherogenesis, diabetes, Alzheimer's, newborn periventricular leukomalacia, breast cancer, and stroke. Whatever the name, the protein is encoded by the gene ALOX15 in both mice and humans. 

Lox inhibitors are difficult to develop due to the mouse and human homologs having different substrate and inhibitor specificities - 12/15 LOX produces predominantly 15-HETE in humans and 12-HETE in mice. So existing inhibitors are not selective for 12/15 LOX with regard to other LOX isoforms. In addition, many are strong antioxidants and therefore may result in off-target effects. 

Technology Description

A collaboration between UC Santa Cruz, Boston Children's Hospital, and the National Institutes of Health performed a systematic chemical screen for 12-LOX inhibitors. The screen revealed a family of compounds that exhibit inhibitory effects on 12/15-lipoxygenase. Accordingly, the present invention relates to the use of these compounds for the inhibition of 12/15-lipoxygenase and for the treatment of a condition involving 12/15-lipoxygenase. Exemplary conditions include, but are not limited to, stroke, periventricular leukomalacia, cardiac arrest with resuscitation, atherosclerosis, Parkinson's disease, Alzheimer's disease, and breast cancer.

Issued patents include methods and compounds

Structure of lead compound: ML351 


Potential therepeutic for:

  • diabetes,
  • Alzheimer's,
  • newborn periventricular leukomalacia,
  • breast cancer,
  • stroke 
  • atherogenesis
Inhibition of 12/15 lipoxygenase




  • Specifically inhibits 12/15-LOX realtive to 15-LOX, 12-LOX, and 5-LOX 
  • Low antioxidant activity
  • Activity in animal models (e.g. protective in stroke model) 
  • Good in vivo ADME profile
  • Good brain/plasma ratio (crosses BBB) 


Intellectual Property Information

Country Type Number Dated Case
United States Of America Issued Patent 10,287,279 05/14/2019 2016-385
European Patent Office Published Application 3036226 06/29/2016 2016-385
Canada Published Application 2015/027146 A1 02/26/2015 2016-385
Switzerland Published Application 2016-385
Germany Published Application 2016-385
France Published Application 2016-385
United Kingdom Published Application 2016-385

Related Materials


Learn About UC TechAlerts - Save Searches and receive new technology matches


  • Holman, Theodore R.

Other Information


12/15-LOX, 12/15-Lipoxygenase, Lipoxygenase, Arachidonic Acid, HETE, 12-HETE, 15-HETE, Diabetes, Atherogenesis, Alzheimer's, Cardiac arrest, Atherosclerosis, Parkinson's disease, Breast Cancer, Stroke, Newborn periventricular leukomalacia

Categorized As